Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Pfizer ( PFE +0.45% ) led the latest round of hikes, raising prices on over 60 drugs — more than any other company. This ...

Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing ...

Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...

Other relevant products are Prevnar 13, a pneumococcal vaccine; Ibrance, breast cancer treatment; and Vyndaqel/Vyndamax, which addresses a rare but serious heart condition. The U.S. market ...

Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...

Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...

The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...

The phase 2 PELOPS trial included 49 patients with stages 1 to 3 HR-positive, HER2-negative breast cancer and were randomly assigned to receive either neoadjuvant endocrine therapy plus Ibrance ...

The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...